Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine, offers a brief synopsis of his plenary lecture, "Genome-Directed Therapeutics for Endocrine Therapy–Resistant Estrogen Receptor–Positive Breast Cancer."

Breast Cancer

Jack Cuzick, PhD

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Charles E. Geyer, Jr, MD, FACP

May

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Matthew J. Ellis, MD, on Endocrine Therapy–Resistant Breast Cancer

Jack Cuzick, PhD, on the IBIS-I Trial

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans

Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer

Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors

Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer

GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers